Arsenic Trioxide as A Selective Anticancer Agent: Rational and Clinical Utility
Keywords:
-Abstract
-
Downloads
References
Giuseppe Avvisati, Francesco Co Coco, Franco Mandelli. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Seminar in Hematol 2001;38:4-12.
Zhu Chen, Guo-Qiang Chen, Zhi-Xiang Shen, Sai-Juan Chen, Zhen-Yi Wang. Treatment of acute promyelocytic leukemia with arsenic compounds. In Vitro and In Vivo studies. Seminar in Hematol 2001;38:26-36.
Melnick A, Licht JD. Deconstructing a disease: RARO, its fusion partners, and their roles in the pathogenesis of acute pormyelocytic leukemia. Blood 1999;93:3167-215.
Chen Z, Tong JH, Dong S, et al. Retinoic acid regulatory pathways, chromosomal translocations and acute promyelocytic leukemia. Genes Chromosomes Cancer 1996;15:147-56.
Brenner MK, Pinke D.Cure of leukemia. Semin Hematol 1997,36(suppl 7):59-72.
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide in the treatment of acute promyelcytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997,89:3354-60.
Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia (APL). Blood 1999:94(suppl 1):698a.
Sun HD, Ma L, Hu XC, et al. Treatment of acute promyelocytic leukemia by Al-1 therapy. Chin J integrat Chin Trad Med Westren Med 1992;12:170-2.
Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide in treatment of acute promyelocytic leukemia (APL): I As O, exerts dose-dependent dual effect on APL cells in vitro and in vivo. Blood 1997;89:3345-53.
Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia : As3 O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARO/PML
proteins. Blood 1996;88:1052-61.
Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-8.
Pershagen G. The epidemiology of human arsenic exposure, in fowler BA(ed): Biological and Environmental Effects of Arsenic. Oxford, UK, Elsevier Science, 1983:199-229.
Zhan P, Wang Sy, Hu LH, et al. Aresenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-60.
Shen ZX, Chen GO, Ni JH, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia(APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
Soignet SL, Frankel S, Tallman MS, et al. Multiple centers trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 1999;94(suppl 1):698a.
Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide. Remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed patients. Blood 1999;94:3315-24.
Soignet SL, Frankel SR, Douer D, et al. United States multicenter studies of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Eng J Med 1998;339:1341-8.
Zhu J, Koken MH, Auignon F, et al. Arsenic induced PML targeting onto nuclear bodies: Implications for the treatment of APL. Pro Natl Acad Sci USA 1997;94:3978-83.
Lu DP, Qiu JY, Jinag B, et al. Effective treatment of acute promyelocytic leukemia with tetra-arsenic tetrasulfide. A mono-instituitional study. Blood 1999;94(suppl1):698a.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
